Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease
- First Online:
- 227 Downloads
The severe, cortical, cholinergic depletion accompanying Parkinson’s disease (PD) is considered as a highly probable correlate of cognitive and behavioural dysfunction. Recent studies have demonstrated that cholinesterase inhibitors (notably rivastigmine) are beneficial in patients suffering from dementia associated with PD (PDD). However, the primary efficacy variables used in such work came from scales designed for Alzheimer’s disease (AD), even though the cognitive symptoms in PD and AD dementia do not overlap completely. The aim of the present study (a double-blind, placebo-controlled clinical trial) was to determine the utility of the Mattis dementia rating scale - the most commonly used scale in PD patients - to assess the efficacy of a 24-week rivastigmine treatment.
Twenty-eight patients with PD, who constituted a subgroup of patients enrolled to the EXPRESS study (Emre et al, N Engl J Med 2004) participated in this study. They suffered from mild to moderately severe dementia (MMSE scores above 10 and below 24), with an onset of cognitive symptoms occurring at least two years after the diagnosis of PD. Patients were randomly assigned to treatment with rivastigmine (3 to 12 mg per day) or placebo. The Mattis dementia rating scale was administered to patients from six centres in France at the baseline and end-point visits.
Compared with placebo, a 24-week rivastigmine treatment led to a significant improvement in the overall score on the Mattis dementia rating scale (p = 0.031), with a trend towards a significant improvement in the “Attention” subscale score (p = 0.061). Correlation analysis showed that in the rivastigmine group, performance on the Mattis “Attention” and “Initiation” subscales appeared to contribute heavily to the improvement in the overall score. Moreover, the latter was also related to an improvement in activities of daily living and a reduction in behavioural disturbances.
By using the Mattis dementia rating scale (which comprises items that are sensitive to executive dysfunction), the present study confirmed that rivastigmine has a beneficial effect on cognitive function in PDD. Despite our study’s small sample size, the Mattis scale was able to detect this improvement and could thus be considered as an interesting outcome measure in further work.
Keywordscognitive dysfunction in PD mattis dementia rating scale dementia cholinesterase inhibitors
- 4.Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, Dekosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–8PubMedCrossRefGoogle Scholar
- 5.Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, Dekosky ST (2005) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol Sep 2; [Epub ahead of print]Google Scholar
- 11.Fahn S, Elton RL, the members of the UPDRS Development Committee (1987) The Unified Parkinson’s disease rating scale In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds), Recent developments in Parkinson’s disease Vol. 2. Florham Park, NJ Macmillan healthcare pp 153–163Google Scholar
- 16.Kaufer DI, Bohnen NI, Ivanco L, Hendrickson R, Lopresti B, Mathis CA, Moore RY, DeKosky ST (2005) Cholinergic Correlates of Cognitive and Neuropsychiatric Disturbances in Parkinson s Disease with and without Dementia. Neurology 64(6, suppl 1): A.137Google Scholar
- 17.Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berl) 106: 83–8Google Scholar
- 19.Mattis S (1976) Mental status examination for organic mental syndrome in the elderly patient In: Bellak L., Karasy T.E. (Eds) Geriatric Psychiatry New York Grune and Stratton pp 77–121Google Scholar
- 20.Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, Littlewood E, Myint P, Newby J, McKeith IG (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18: 988–93PubMedCrossRefGoogle Scholar
- 22.Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76: 934–9PubMedCrossRefGoogle Scholar